AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2020
Oct 2, 2020
33861_dirs_2020-10-01_a756ad0e-cdd3-4444-ace6-7ab24660fe67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01
Reporting Person: Prokupets Elena (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $ | Common Stock (118574) | Indirect | ||
| Series A Preferred Stock | $ | Common Stock (592873) | Indirect | ||
| Stock Option (Right to Buy) | $2.11 | 2026-07-12 | Common Stock (8561) | Direct |
Footnotes
F1: Shares of Series A Preferred Stock and Series B Preferred Stock are convertible into Common Stock on a 8.4335-to-one basis into the aggregate number of shares of Common Stock shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
F2: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.
F3: 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter.